MOH
- Marketing authorisation holder: 3D IMAGING DRUG
- Status: likely_approved
Fludeoxyglucose F-18 (F-18) regulatory status in Israel.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH has authorised it.
3D IMAGING DRUG holds the Israeli marketing authorisation.